Notes

Your regulating healthspan and life-span by eating proteins.
Nevertheless, the higher percentage inclusion of the pulp showed higher antihypertensive effects.
Naloxegol, an oral once-daily peripherally acting mu-opioid receptor antagonist, is indicated for the treatment of opioid-induced constipation (OIC) with inadequate response to laxative(s), in cancer and non-cancer patients. This study mainly aimed to assess in real-life conditions the efficacy and safety of naloxegol in cancer pain patients and the evolution of their quality of life.

A non-interventional, 4-week follow-up study was conducted in 24 French oncology and pain centers between 2018 and 2019. Eligible patients were aged ≥ 18years, treated with opioids for cancer pain, and started naloxegol for OIC with inadequate response to laxatives. The rate of the response to naloxegol (primary criterion) was assessed at W4. The evolution of quality of life was measured using the Patient Assessment of Constipation Quality of Life (PAC-QOL).

A total of 124 patients were included (mean age, 62 ± 12years; ECOG ≤ 2, 79%; primary cancer, lung 18%, breast 16%, prostate 11%, head and neck 9%, digestive 9%…; metastatic stage, 80%). PFI-2 At inclusion, the median opioid dosage was 60mg of oral morphine or equivalent. At W4, the response rate was 73.4% (95% CI [63.7-83.2%]), and 62.9% (95% CI [51.5-74.2%]) of patients had a clinically relevant change in quality of life (decrease in PAC-QOL score ≥ 0.5 point). Adverse events related to naloxegol were reported in 8% of patients (7% with gastrointestinal events; one serious diarrhea).

This real-world study shows that naloxegol is effective and well tolerated in cancer pain patients with OIC and that their quality of life improves under treatment.
This real-world study shows that naloxegol is effective and well tolerated in cancer pain patients with OIC and that their quality of life improves under treatment.
Several clinical trials evaluated the effect of zinc supplementation on mortality in children, but the results were inconsistent. We aimed to conduct a systematic review and meta-analysis on the impact of zinc supplementation on mortality in under 5-year children.

A comprehensive search was conducted using the electronic (PubMed, Scopus, Web of Science) databases, and Google Scholar, up to June 2020. Randomized clinical trials (RCTs) that reported the effect of zinc supplementation on death incidence in under 5-year children were included in the analysis. Screening was performed based on title/abstract and full-text. A random effects model was applied to calculate the summary relative risk (SRR). Risk of Bias 2.0 tool was used to rate the quality of trials. The body of evidence was assessed by the GRADE approach.

Combining 30 RRs from 28 RCTs including 237,068 participants revealed that zinc supplementation has significantly reduced the risk of all-causes mortality by 16% in children (SRR 0.84, 95% CI 0ion, a maximum of 11months of supplementation, a follow-up less than one year and especially in LBW infants.
This meta-analysis on RCTs revealed that zinc supplementation in under 5-year children has significantly reduced the risk of all-cause mortality. Notable decreases were found in trials with a dose of 10 mg/d or more zinc supplementation, a maximum of 11 months of supplementation, a follow-up less than one year and especially in LBW infants.
Supplementing animal diets with high-dose fish oil, rich in long chain omega-3 (ω-3) docosahexaenoic acid (DHA), enhances cardiac contractile efficiency and attenuates dysfunction, attributable to ischaemia. However, it remains unclear whether smaller doses, equivalent to what is achievable via regular fish consumption in the human diet, offer similar protection.

Male Sprague-Dawley (12-15w) rats were fed isoenergetic diets (ad libitum) containing 10% fat by weight (22% energy) for 4-5w. Control diet (CON) contained 5.5% beef tallow; 2.5% ω-6 sunflower seed oil; 2% olive oil. Fish oil diets included high-DHA tuna oil exchanged for olive oil to provide 0.32% (FO1; human equivalent EPA + DHA 570mg/d) or 1.25% (FO2; equivalent EPA + DHA 2.3g/d) wt/wt dose of fish oil. Anaesthetised rats (pentobarbital 60mg/kg i.p.) were subjected to 45min coronary artery occlusion then reperfusion in vivo as a whole animal model of regional myocardial ischaemia, with left ventricular haemodynamic function measured by conductance catheter.

Ischaemia-induced reductions in rate pressure product recovered faster in the FO2 group and post-ischaemic left ventricular pressure-volume loop integrity (shifted downwards and right in CON) was partially protected in both fish oil groups.

Ischaemia-induced contractile dysfunction in rats is limited from fish oil doses equivalent to regular consumption of fish in the human diet. These observations highlight plausible and clinically relevant physiological changes that rationalise nutritional conditioning of the heart with DHA for on-going cardioprotection.
Ischaemia-induced contractile dysfunction in rats is limited from fish oil doses equivalent to regular consumption of fish in the human diet. These observations highlight plausible and clinically relevant physiological changes that rationalise nutritional conditioning of the heart with DHA for on-going cardioprotection.The need to generate internal revenue by most individuals and government in Nigeria has led to the establishment of quarries in different parts of Ebonyi state of Nigeria. This study was aimed at determining the risk associated with the heavy metal burden in the state. Soil samples from the quarrying environments designated as MS1, MS2, and MS3 were analyzed for the metal profile using inductively coupled plasma optical emission spectrometry (ICP-OES). The result showed that the mean concentration of metals which is a representation of the whole sites showed a higher concentration of Ca (40.065 ± 1.011 ppm), Mg (12.450 ± 8.815 ppm), K (16.631 ± 14.670 ppm), and Mn (19.539 ± 3.225 ppm) while Na (1.326 ± 0.117 ppm) was low. The heavy metal profile showed Pb (0.120 ± 0.027 ppm), Fe (27.718 ± 1.523 ppm), Zn (2.227 ± 0.570 ppm), Cu (6.267 ± 1.402 ppm), Ni (1.856 ± 0.472 ppm), Mo (1.758 ± 0.258 ppm), Cd (0.023 ± 0.006 ppm), Cr (0.037 ± 0.011 ppm), etc. Hg was found to be below detectable limit while the Cs was not radioactive.
Here's my website: https://www.selleckchem.com/products/pfi-2.html